Takeda Pulls FDA Application for Expanded Use of Cancer Drug Velcade Genetic Engineering News Millennium: The Takeda Oncology Company has decided to withdraw its sNDA for Velcade in combination with rituximab for the treatment of relapsed follicular lymphoma, citing “business reasons.” The decision was made after further evaluation based on ... Millennium Provides Update on sNDA for VELCADE in Relapsed Follicular Lymphoma Millenium, Takeda Pharma Withdraw SNDA For Relapsed Follicular Lymphoma Therapy |
